| Date | Title | Description |
| 13.08.2025 | Veterans Exploring Treatment Solutions (VETS) Announces Sponsors for 4th Annual Torchbearer Ball | Veterans Exploring Treatment Solutions (VETS)
Black-tie gala returns November 15, 2025, at the Hotel del Coronado—uniting changemakers, honoring documentary filmmakers, and raising critical funds for life-changing therapies for veterans Gal... |
| 26.06.2025 | DemeRx Appoints Biopharma Industry Veteran Vic Pirotsky to Board of Directors | Pirotsky brings more than two decades of biopharma expertise and a proven track record of leading 8+ successful new drug applications •He advocates for an "Addiction Moonshot" collaboration between government and business •Appoint... |
| 29.03.2023 | 9 psychedelics startups that are winning over top venture investors | A handful of psychedelics companies have received interest from mainstream investors. jackfoto/iStock/Getty Images Plus This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
The psychedelics in... |
| 17.02.2023 | These investor-backed mental health startups are healing our brains | At least 1 in 5 people will experience mental illness at any time.
Yet for many, treatment is prohibitive due to long-waiting lists for mental health professionals, hospital bed shortages, and medication that comes with adverse side effects... |
| 24.01.2023 | The rise of venture debt: When biotechs should—and shouldn't—use it | Biotechs are operating on razor-thin margins, struggling in a market that just two years ago was flush with cash for big ideas. But now, these same companies are facing more desperate times and seeking out innovative ways to extend their ca... |
| 11.01.2023 | The CEO of a psychedelics giant that just suffered a big setback lays out why investors should bet on his long-term vision | Atai Life Sciences CEO Florian Brand. ATAI Life Sciences
This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Last week, the psychedelics giant Atai announced disappointing results from a much... |
| 04.10.2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |
| 06.09.2022 | atai Life Sciences to Participate in September Investor Events | NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. ATAI ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the follow... |
| 15.08.2022 | atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital | - Non-dilutive financing facility, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments
- Flexible draw availability provides optionality to o... |
| 15.08.2022 | Atai prunes pipeline, drops out of partnerships as it takes on $175M loan and focuses on looming data readouts | Planning for the long haul, mental health-focused biotech atai Life Sciences has taken a hard look at its sizable portfolio — and decided to cut off parts of it.
The decision to stop funding certain programs and discovery e... |
| 19.05.2022 | Can We Fix Ovarian Aging? Here Is One Startup Up For The Task! | Concept of a healthy female reproductive system. getty |
| 27.01.2022 | Atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments | Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs)
Early focus will be on designing unique, novel compounds aimed at the serotonin 5-HT2A... |
| 12.01.2022 | Atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program | • Enables expansion of PCN-101 clinical development to the U.S.
• atai plans to initiate clinical drug-drug interaction (DDI) study in early 2022 to assess pharmacokinetics of PCN-101 when used concurrently with other drugs
• DDI trial will... |
| 29.11.2021 | atai Life Sciences Increases Its Ownership Position in COMPASS Pathways | Demonstrates atai’s confidence in COMPASS’ Phase 2b data and its potential for patients with treatment-resistant depression
atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health di... |
| 12.08.2021 | Manufacturing issues hold back distribution of overdose injection; San Diego biotech triples footprint | In April, Pfizer was forced to stop production of the injectable opioid antidote naloxone, after a manufacturing issue. Now, a shortage has raised the alarm for advocates, who are saying the lack of access coupled with an all-time high of d... |
| 12.08.2021 | UPDATED: Out to revamp plant-based drug manufacturing, Antheia locks in partnership with synthetic biology giant Ginkgo | With supply chain shortages at the forefront of nearly every business in the world right now, whether it be chicken wings or CAR-T cell therapy, synthetic biology upstart Antheia is looking to aid in the fight. It just announced a deal with... |
| 12.08.2021 | Merck partner Artiva blueprints San Diego R&D, manufacturing site to take NK cell operation to the next level | In January, Artiva Biotherapeutics CEO Fred Aslan said his company is looking to create CAR-NK therapies with best-in-class efficacy made in a wholly owned manufacturing process. Artiva is now another step closer to that goal.
Artiva will o... |
| 12.08.2021 | A unicorn bags another $220M to fund its plans to upend the clinical trial process | The focus on decentralized trials amid the pandemic has led investors to make some big bets on companies promising to shake up the contract research space. Reify Health is the latest, coming away with $220 million to end wha... |
| 12.08.2021 | Peter Thiel-backed ATAI launches new Salvia-focused biotech; Purdue bankruptcy trial expected to begin today — report | ATAI Life Sciences, the Peter Thiel-backed umbrella developer of psychedelics and other drugs for mental health conditions, launched a new portfolio company Thursday.
The new outfit is called Revixia Life Sciences, and... |
| 12.08.2021 | Manufacturing issues hold back distribution of overdose injection; San Diego biotech triples footprint | President Joe Biden on Thursday revealed key details of what he wants to see reformed in the pharmaceutical industry when it comes to drug prices, calling not only for Medicare negotiations, which seems to be at the forefront of Senate plan... |
| 10.08.2021 | Indigenous Reciprocity Initiative of the Americas Website Launch | The Indigenous Reciprocity Initiative gives back to Indigenous people through nurturing ecological wellbeing, including land rights activism, bolstering food security, and more. The issue of Indigenous intellectual property needs to be addr... |
| 15.07.2021 | Atai Life Sciences N : Leading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million Raised to Tackle the Growing Global Mental Health Crisis | CHICAGO, July 15, 2021 /PRNewswire/ -- Palo Santo, the leading U.S.-based psychedelic investment fund, announced its launch with an initial $35 million in capital raised and an active portfolio of 20 companies. The diversified venture fund ... |
| 18.06.2021 | Thiel-backed psychedelics startup Atai valued at $3.19 bln in Nasdaq debut | June 18 (Reuters) - Shares of Atai Life Sciences B.V. , backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion.
The ... |
| 18.06.2021 | Thiel-backed psychedelics startup Atai valued at $3.19 billion in Nasdaq debut | (Reuters) -Shares of Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion.
The Berlin-bas... |
| 18.06.2021 | Psychedelics giant Atai is targeting a $2.3 billion valuation in its IPO. We pored over its 446-page filing to find 7 key takeaways. | Psilocybin found in magic mushrooms is a type of psychedelic Alexander Volkov/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Atai Life Sciences has raised hundred... |
| 18.06.2021 | Thiel-backed psychedelics startup Atai valued at over $3 bln in Nasdaq debut | June 18 (Reuters) - Shares of Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, jumped 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion.
(Repo... |
| 11.06.2021 | German psychedelic startup Atai targets valuation of $2.3 billion in U.S. IPO | (Reuters) - Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, said on Friday it was looking to raise as much as $214.3 million through a U.S. initial public offering, targeting a valuation of about $2.3 billion.
The Berli... |
| 03.06.2021 | Psychedelic healthcare fund Neo Kuma sees early success amid sector growth | The UK’s first investment fund dedicated solely to psychedelic healthcare, Neo Kuma is reporting that a number of its early investments are returning yields between 180% and 680%, with three of the seven companies in its portfolio planning ... |
| 22.04.2021 | Peter Thiel's psychedelic drug startup Atai eyes $100M IPO | Peter Thiel (Neilson Barnard/Getty Images)
Investor interest in psychedelic-based medicine has increased over the last several years amid growing support from regulators, clinicians and patients. In the latest move in the space, Atai Life S... |
| 09.04.2021 | Peter Thiel-backed psychedelic startup ATAI Life Sciences takes majority stake in a brain-computer interface startup Psyber | We covered ATAI Life Sciences (ATAI) back in the winter of 2020 after the Peter Thiel-backed startup raised a $125 million round to develop psychedelics treatment for people suffering from mental health disorders.
Based in Munich, Germany,... |
| 04.03.2021 | atai Life Sciences Closes $157M Series D Financing Round | atai Life Sciences, a Berlin, Germany-based clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, closed a $157m Series D financing round.
The round was led by e... |
| 03.03.2021 | Thiel-backed psychedelic startup Atai raises another $157m | Berlin-headquartered biotech firm Atai Life Sciences, which specialises in psychedelic treatments for mental health disorders, has raised $157m amid the global race to commercialise psychedelics.
The company’s Series D raise follows a $125m... |
| 15.01.2021 | Mental health companies that raised funding in 2020 | Headspace, Lyra, Koa Health, Ginger, and Spring Health were among those that saw new investments
2020 was a tough year, to state the obvious. With all the death from the pandemic, COVID-caused isolation, civil unrest, and all the election s... |
| 27.11.2020 | Peter Thiel backs German startup that develops psychedelic therapy for mental health disorders; firm secures €105M | The coronavirus pandemic has sent a shockwave across the world, taking an unprecedented toll on our lives including mental health since the majority of us are confined to work and exercise from home.
According to a report by WHO Euro (World... |
| 24.11.2020 | Peter Thiel backs Berlin startup ATAI Life Sciences in $125M round to develop psychedelics treatment for people suffering from mental health disorders | Almost a billion people suffer from mental health problems worldwide, according to the World Health Organization. ATAI Life Sciences is a biotechnology startup founded in 2018 in response to the clear and growing unmet needs of mental healt... |
| 24.11.2020 | Another Bet on Psychedelic Drugs: Atai Raises $125 Million | With investors taking psychedelic drugs seriously as potential treatments for intractable cases of depression, addiction, or post-traumatic disorder, the stock plays are flying.
Since the September initial offering of Compass Pathways’ depo... |
| 23.11.2020 | ATAI Life Sciences Closes $125 Million Series C Financing | ATAI Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $125 million Series C financing round, including $32 mill... |
| 23.11.2020 | ATAI snags $125M to bankroll mental health pipeline | ATAI Life Sciences is topping off a busy year with a $125 million financing, which will support the preclinical and clinical development for its mental health pipeline, including programs in opioid use disorder and depression. The series C ... |
| 23.11.2020 | ATAI snags $125M to bankroll mental health pipeline
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | ATAI Life Sciences is topping off a busy year with a $125 million financing, which will support the preclinical and clinical development for its mental health pipeline, including programs in opioid use disorder and depression. The series C ... |
| 24.08.2020 | ATAI Life Sciences launches EmpathBio to treat post-traumatic stress disorder with novel MDMA product | |
| 28.02.2020 | ATAI has raised $100 million to turn psychedelics into treatments for depression and anxiety. Now the unusual biotech is gearing up to raise millions more for the next phase of human testing. | Shutterstock
Psilocybin, the main psychoactive ingredient in hallucinogenic mushrooms, could help treat depression.
Advertisement
Florian Brand helped start ATAI Life Sciences with one vision in mind: to effectively treat mental-health diso... |
| 02.04.2019 | Germany-Based ATAI Life Sciences Raises $43 Million To Cure Mental Health Disorders | ATAI Life Sciences, a Munich, Germany-based global biotech platform company that is focused on curing mental health disorders, announced it has raised $43 million (EUR 38 million) in funding. Christian Angermayer (founder), Lars Wilde (co-f... |
| 29.03.2019 | Term Sheet — Friday, March 29 | THE SMALL IPO IS DEAD
I’ll never forget Lyft president John Zimmer’s comment at Fortune’s Brainstorm Tech conference in Aspen last year: “Four or five years ago, we woke up one day and Uber had 30 times the amount of cash as us. Thirty time... |
| 28.03.2019 | Daily funding roundup - March 28th, 2019 | BillionToOne raised $15M; Polyneuron Pharmaceuticals secured $22.6M;Prevail Therapeutics lands $50M
Artiphon: Artiphon is empowering a new generation to explore music-making with smart instruments and adaptive software. Artiphon has raised ... |
| 28.03.2019 | Atai Life Sciences Closes $43M Series B Financing | Atai Life Sciences, a Berlin, Germany- London, UK- and New York-based biotech platform dedicated to curing mental health disorders, completed its series B financing round of $43m (€38m).
The round was led by Michael Auerbach’s New York-base... |
| 27.03.2019 | ATAI Life Sciences Closes $43 Million Series B Financing Round | NEW YORK & LONDON & BERLIN--(BUSINESS WIRE)--ATAI Life Sciences, the global biotech platform dedicated to curing mental health disorders, has completed its series B financing round of $43 million (EUR 38 million).
Founded in 2018 by... |
| 27.03.2019 | ATAI Life Sciences Closes $43 Million Series B Financing Round | NEW YORK & LONDON & BERLIN--(BUSINESS WIRE)--ATAI Life Sciences, the global biotech platform dedicated to curing mental health disorders, has completed its series B financing round of $43 million (EUR 38 million).
Founded in 2018 by... |
| 03.01.2019 | ATAI Life Sciences acquires majority stake in Perception Neuroscience to develop arketamine therapy for neuropsychiatric diseases | Munich and New York, 03 January 2019 - ATAI Life Sciences AG has acquired a majority stake in New York based Perception Neuroscience, a biopharmaceutical company focused on developing innovative therapies in neuropsychiatry. Perception was ... |
| - | Civilized founders pushed out | As the legal cannabis market grows in the US, there are many ways for investors to gain exposure to the industry. Bloomberg Creative/Getty Images
Redeem now
Welcome to Insider Cannabis, our weekly newsletter where we're bringing you an insi... |
| - | The legal psychedelics industry: capitalism on drugs | On April 19, the Fontainebleau Miami Beach hotel hosted the inaugural Benzinga Psychedelics Capital Conference, advertised as “bringing together leaders of the BIGGEST publicly-traded Psychedelics companies with investors from across North ... |
| - | Startups are measuring your brain waves and analyzing your voice to figure out how to better treat mental-health disorders like depression | Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Startups are measuring brain waves and the sound of your voice to better treat depression. The measurements, called... |
| - | The biggest private psychedelics company in the world just raised a record $157 million, pushing psychedelics further into the mainstream | Psilocybin found in magic mushrooms is a type of psychedelic Alexander Volkov/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Atai Life Sciences, the largest private psychede... |
| - | 2022 has been a 'lost year in terms of valuation' for Christian Angermayer. The 44-year-old German billionaire told us why he is doubling down on his investments in psychedelic stocks and remains 'ext... | Christian Angermayer, founder of Apeiron Investment Group Apeiron Investment Group This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Risk assets are falling in tandem as the macro environme... |
| - | Psychedelic healthcare fund Neo Kuma sees early success amid sector growth | The UK’s first investment fund dedicated solely to psychedelic healthcare, Neo Kuma is reporting that a number of its early investments are returning yields between 180% and 680%, with three of the seven companies in its portfolio planning ... |
